Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+0.15%
$64.84
100% positive prob.
5-Day Prediction
+8.89%
$70.50
100% positive prob.
20-Day Prediction
+6.92%
$69.23
95% positive prob.
SEC 8-K filings with transcript text
Feb 26, 2026 · 100% conf.
1D
+0.15%
$64.84
Act: -2.64%
5D
+8.89%
$70.50
Act: -7.80%
20D
+6.92%
$69.23
false 0001888886 True
0001888886
2026-02-26 2026-02-26
0001888886
gpcr:AmericanDepositarySharesAdssEachRepresentingThreeOrdinarySharesParValue0.0001PerOrdinaryShareMember
2026-02-26 2026-02-26
0001888886
gpcr:OrdinarySharesParValue0.0001PerShareMember
2026-02-26 2026-02-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 26, 2026
Structure Therapeutics Inc.
(Exact name of registrant as specified in its charter)
Cayman Islands
001-41608
98-1480821
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
601 Gateway Blvd., Suite 900
South San Francisco, California
94080
(Address of principal executive offices)
(Zip Code)
(Registrant’s telephone number, including area code): (650) 457-1978
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Name Of Each Exchange
Trading Symbol(s)
On Which Registered
American Depositary Shares (ADSs), each representing three
ordinary shares, par value $0.0001 per ordinary share
Nasdaq Global Market
Ordinary shares, par value $0.0001 per share*
True
Nasdaq Global Market*
* Not for trading, but only in connection with the registration of the American Depositary Shares
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition.
On February 26, 2026, Structure Therapeutics Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the fourth quarter ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No.
Description
99.1
Press Release dated February 26, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Structure Therapeutics Inc.
Date: February 26, 2026 By: /s/ Raymond Stevens
Raymond Stevens, Ph.D.
Chief Executive Officer
Nov 6, 2025
false 0001888886 True
0001888886
2025-11-06 2025-11-06
0001888886
gpcr:AmericanDepositarySharesAdssEachRepresentingThreeOrdinarySharesParValue0.0001PerOrdinaryShareMember
2025-11-06 2025-11-06
0001888886
gpcr:OrdinarySharesParValue0.0001PerShareMember
2025-11-06 2025-11-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 6, 2025
Structure Therapeutics Inc.
(Exact name of registrant as specified in its charter)
Cayman Islands
001-41608
98-1480821
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
601 Gateway Blvd., Suite 900
South San Francisco, California
94080
(Address of principal executive offices)
(Zip Code)
(Registrant’s telephone number, including area code): (650) 457-1978
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Name Of Each Exchange
Trading Symbol(s)
On Which Registered
American Depositary Shares (ADSs), each representing three
ordinary shares, par value $0.0001 per ordinary share
Nasdaq Global Market
Ordinary shares, par value $0.0001 per share*
True
Nasdaq Global Market*
* Not for trading, but only in connection with the registration of the American Depositary Shares
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition.
On November 6, 2025, Structure Therapeutics Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the third quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No.
Description
99.1
Press Release dated November 6, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Structure Therapeutics Inc.
Date: November 6, 2025 By: /s/ Raymond Stevens
Raymond Stevens, Ph.D.
Chief Executive Officer
Aug 6, 2025
false 0001888886 True
0001888886
2025-08-06 2025-08-06
0001888886
gpcr:AmericanDepositarySharesAdssEachRepresentingThreeOrdinarySharesParValue0.0001PerOrdinaryShareMember
2025-08-06 2025-08-06
0001888886
gpcr:OrdinarySharesParValue0.0001PerShareMember
2025-08-06 2025-08-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 6, 2025
Structure Therapeutics Inc.
(Exact name of registrant as specified in its charter)
Cayman Islands
001-41608
98-1480821
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
601 Gateway Blvd., Suite 900
South San Francisco, California
94080
(Address of principal executive offices)
(Zip Code)
(Registrant’s telephone number, including area code): (650) 457-1978
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Name Of Each Exchange
Trading Symbol(s)
On Which Registered
American Depositary Shares (ADSs), each representing three
ordinary shares, par value $0.0001 per ordinary share
Nasdaq Global Market
Ordinary shares, par value $0.0001 per share*
True
Nasdaq Global Market*
* Not for trading, but only in connection with the registration of the American Depositary Shares
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition.
On August 6, 2025, Structure Therapeutics Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the second quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. Description
99.1 Press Release dated August 6, 2025
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Structure Therapeutics Inc.
Date: August 6, 2025 By: /s/ Raymond Stevens
Raymond Stevens, Ph.D.
Chief Executive Officer
This page provides Structure Therapeutics Inc. (GPCR) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on GPCR's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.